Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies

INTRODUCTION: New medications for anaemia associated with chronic kidney disease (CKD) are desirable, owing to the limitations of erythropoiesis-stimulating agents (ESAs), the current standard of care. Molidustat is a novel hypoxia-inducible factor prolyl-hydroxylase inhibitor that stimulates erythr...

Descripción completa

Detalles Bibliográficos
Autores principales: Akizawa, Tadao, Taguchi, Megumi, Matsuda, Yoshimi, Iekushi, Kazuma, Yamada, Takashi, Yamamoto, Hiroyasu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Renal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6588954/
https://www.ncbi.nlm.nih.gov/pubmed/31203241
http://dx.doi.org/10.1136/bmjopen-2018-026602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6588954/
https://www.ncbi.nlm.nih.gov/pubmed/31203241
http://dx.doi.org/10.1136/bmjopen-2018-026602

Ejemplares similares